Curaleaf launches UK's first CE-certified cannabis inhaler

Curaleaf Laboratories has announced the launch of the UK’s first CE-certified liquid medical cannabis inhaler, aiming to address growing patient and clinical demand for a discreet and reliable inhalation method. Available on prescription to UK patients, the new rechargeable device uses Curaleaf’s already available EU-GMP liquid extract cartridges, and has a minimum lifespan of six months from first use, delivering up to 240 inhalations with a 1.0mL cartridge. Juan Pablo M., International CEO at Curaleaf, said: “The launch of this certified Curaleaf device reflects the next phase of innovation and positions Curaleaf at the forefront of a differentiated, pharma-grade delivery platform that addresses growing global demand for precision cannabis therapies.” Read the full article: https://lnkd.in/eJEFPZF7

Our next phase of innovation – UK launch 🌍 Today, we are proud to announce the UK launch of the Curaleaf Que Medical Inhalation Device (QMID) – the first CE-certified liquid cannabis inhaler available to prescribers and patients.    Via Curaleaf Laboratories, the UK is the first market in our international rollout, with launches planned across the globe in the coming months.   The QMID offers a precise, discreet, and clinically approved way to inhale cannabis-based medicines — addressing one of the biggest unmet needs in the medical cannabis community. In partnership with Jupiter Research, the device is:    ✅ CE-certified, Class IIa approved ✅ Offers consistent, precise timed dosing ✅  Simple, discreet, with a patient-friendly design This milestone reinforces our mission to make safe, regulated cannabis therapies available to patients worldwide. 🔗: https://lnkd.in/e_Z62PJG   #CuraleafInternational #MedicalCannabis #HealthcareInnovation #PatientAccess

The next phase of medical cannabis innovation reaches the UK! 🎉 Curaleaf International has launched the Curaleaf Que Medical Inhalation Device (QMID)—the first CE-certified cannabis liquid inhaler available to patients.    This milestone reflects Curaleaf’s leadership in advancing medical cannabis, supported by Jupiter R&D as a trusted solutions partner. Together, we’re delivering innovation that meets the highest standards of compliance and patient care while driving global progress in medical cannabis. With this launch, Curaleaf Laboratories begins its international rollout and will expand into additional markets in the months ahead. ✨ Link to learn more: 🔗: https://lnkd.in/e_Z62PJG

Curaleaf Laboratories has today announced the UK launch of the Curaleaf Que Medical Inhalation Device (QMID), the first CE-certified liquid inhaler for cannabis-based medicines. Since medical cannabis was legalised in the UK in 2018, one of the biggest unmet patient needs has been a discreet and reliable inhalation option — now addressed with the launch of the Curaleaf QMID. Available on prescription, the device offers patients a precise, discreet, and clinically approved way to inhale cannabis-based treatments. Speaking about the new inhalation device, Jonathan Hodgson, UK Managing Director at Curaleaf International, said: “Unlike unregulated or consumer-grade vaporisers, this device is purpose-built for clinical use, with standardised delivery, medical-grade components, and compatibility with formulations that meet European Pharmacopoeia standards.” Read here for the full article 🔗 https://lnkd.in/e4rB5J5J 

We were very pleased to see LBC’s recent coverage of the medicinal cannabis industry, including an inside look at our facility. A huge thank you to the team at LBC and, most importantly, to the patient who shared their experience so openly; stories like theirs are at the heart of why this matters. One of the biggest challenges we face is awareness. Even now, many people still don’t realise that medical cannabis has been legally available on prescription in the UK since November 2018. Coverage like this helps break down stigma and makes patients, clinicians, and the wider public aware that this is a serious, regulated medicine prescribed by specialists under strict frameworks. It was also fantastic to see the Department of Health and Social Care announce over £8.5m in funding for two world-first clinical trials into cannabis-based medicinal products. High-quality clinical evidence is essential for wider NHS adoption and patient access and this funding represents a major step forward. At Dalgety, we believe that transparency, compliance, and robust science are the foundations for a responsible and sustainable medical cannabis industry in the UK. It’s encouraging to see steps being taken that can help shape a more evidence-led future for this medicine. https://lnkd.in/gFm6Fp7b

Great to see Dalgety featured in LBC this week, helping to raise awareness around medical cannabis in the UK. Too many people still don’t realise it’s been available on prescription since 2018 or there is an £8.5m investment into two world-first clinical trials to build the evidence base for wider access. Hearing first-hand how this medicine has changed someone’s life brings home why awareness and education are so important. For many, the stigma remains, and coverage like this helps shift the conversation toward seeing cannabis as a serious, regulated medicine prescribed by specialists. Proud to see Dalgety continuing to play its part in shaping a responsible, transparent, and evidence-led future for the industry. https://lnkd.in/ge5Yhbpb

How Is Cannabis Affecting the Medical Field The medical cannabis industry is experiencing significant growth as research continues to validate its therapeutic potential. Cannabinoids, active compounds found in the plant, are being effectively used to manage chronic pain, reduce chemotherapy-induced nausea, and control seizures in certain forms of epilepsy. Major pharmaceutical companies are increasingly investing in the development of cannabis-based prescription drugs. While regulatory frameworks are still evolving globally, the acceptance of medical cannabis is expanding, offering new treatment avenues for patients and creating a rapidly evolving multi-billion dollar market. This shift highlights a growing focus on harnessing natural compounds for advanced medical solutions #SmellproofBag#Active carbon lined smell proof case#Carbon Lined Bag# Smellproofbackpack#SmellproofDuffleBag# #Smokingaccessories#Cannabisindustry#Vicevapes# #Cannabis#

Time to stop doing observational studies and do real RCTs! To mainstream cannabinoid medicines, we must follow good scientific pathways. "Yet, despite rigorous self-reporting from patients who attribute their reduction or cessation of prescribed medication to the use of medicinal cannabis, most results are mainly drawn from observational studies." Medical Cannabis as a Substitute for Prescription Agents: A Systematic Review and Meta-analysis https://lnkd.in/e8YGbZ8Z #cannabis #medicine #patients #doctors @nejm @JAMA_current @CannabisJrnl

How To Get Reliable, Accurate Advice On Medical Cannabis Treatment https://lnkd.in/eFAqB5uX Dr. Jordan Tishler from inhaleMD discusses the importance of obtaining medical cannabis advice from knowledgeable and reputable sources.

How To Get Reliable, Accurate Advice On Medical Cannabis Treatment https://lnkd.in/eFAqB5uX Dr. Jordan Tishler from inhaleMD discusses the importance of obtaining medical cannabis advice from knowledgeable and reputable sources.